World Investment Advisors Trims Stock Position in United Therapeutics Corporation $UTHR

World Investment Advisors decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 40.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,393 shares of the biotechnology company’s stock after selling 935 shares during the quarter. World Investment Advisors’ holdings in United Therapeutics were worth $400,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $29,000. SVB Wealth LLC purchased a new stake in United Therapeutics in the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Brooklyn Investment Group grew its position in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 98 shares during the last quarter. Finally, WPG Advisers LLC purchased a new position in shares of United Therapeutics during the first quarter worth approximately $60,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent research reports. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. Cantor Fitzgerald boosted their price target on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Bank of America upped their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Wednesday, October 29th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $501.90.

United Therapeutics Trading Down 1.5%

NASDAQ UTHR opened at $438.66 on Tuesday. The stock has a market capitalization of $18.89 billion, a price-to-earnings ratio of 16.62, a PEG ratio of 4.96 and a beta of 0.66. The business’s 50 day moving average is $412.73 and its two-hundred day moving average is $339.81. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $479.50.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the firm earned $6.39 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $450.34, for a total transaction of $4,953,740.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $16,563,955.54. This represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 4,000 shares of the stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $448.96, for a total transaction of $1,795,840.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at $58,364.80. This represents a 96.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 368,435 shares of company stock valued at $152,863,012. 10.30% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.